These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 9806949)

  • 1. Pharmacokinetics of the bicyclic peptide tachykinin NK2 receptor antagonist MEN 11420 (nepadutant) in rats.
    Lippi A; Criscuoli M; Guelfi M; Santicioli P; Maggi CA
    Drug Metab Dispos; 1998 Nov; 26(11):1077-81. PubMed ID: 9806949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist.
    Catalioto RM; Criscuoli M; Cucchi P; Giachetti A; Gianotti D; Giuliani S; Lecci A; Lippi A; Patacchini R; Quartara L; Renzetti AR; Tramontana M; Arcamone F; Maggi CA
    Br J Pharmacol; 1998 Jan; 123(1):81-91. PubMed ID: 9484857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nepadutant pharmacokinetics and dose-effect relationships as tachykinin NK2 receptor antagonist are altered by intestinal inflammation in rodent models.
    Lecci A; Carini F; Tramontana M; D'Aranno V; Marinoni E; Crea A; Bueno L; Fioramonti J; Criscuoli M; Giuliani S; Maggi CA
    J Pharmacol Exp Ther; 2001 Oct; 299(1):247-54. PubMed ID: 11561086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the antibronchoconstrictor activity of MEN 11420, a tachykinin NK2 receptor antagonist, in guinea-pigs.
    Tramontana M; Patacchini R; Giuliani S; Lippi A; Lecci A; Santicioli P; Criscuoli M; Maggi CA
    Eur J Pharmacol; 1998 Jul; 352(2-3):279-88. PubMed ID: 9716365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a tachykinin NK(2) receptor antagonist, nepadutant, on cardiovascular and gastrointestinal function in rats and dogs.
    Giuliani S; Guelfi M; Toulouse M; Buéno L; Lecci A; Tramontana M; Criscuoli M; Maggi CA
    Eur J Pharmacol; 2001 Mar; 415(1):61-71. PubMed ID: 11245853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
    Cialdai C; Tramontana M; Patacchini R; Lecci A; Catalani C; Catalioto RM; Meini S; Valenti C; Altamura M; Giuliani S; Maggi CA
    Eur J Pharmacol; 2006 Nov; 549(1-3):140-8. PubMed ID: 16979621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of the tachykinin NK2 receptor antagonist nepadutant in acute rectocolitis induced by diluted acetic acid in guinea-pigs.
    Cutrufo C; Evangelista S; Cirillo R; Ciucci A; Conte B; Lopez G; Manzini S; Maggi CA
    Neuropeptides; 2000 Dec; 34(6):355-9. PubMed ID: 11162292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the design, synthesis and biological activity of the bicyclic hexapeptide tachykinin NK2 antagonist MEN 10627.
    Quartara L; Pavone V; Pedone C; Lombardi A; Renzetti AR; Maggi CA
    Regul Pept; 1996 Aug; 65(1):55-9. PubMed ID: 8876036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine.
    Khalili P; Naimi E; Sun WY; Knaus EE; Wiebe LI
    Biopharm Drug Dispos; 2003 Dec; 24(9):385-95. PubMed ID: 14689467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
    Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
    Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of nepadutant, a neurokinin 2 tachykinin receptor antagonist, on immediate-early gene expression after trinitrobenzenesulfonic acid-induced colitis in the rat.
    Birder LA; Kiss S; de Groat WC; Lecci A; Maggi CA
    J Pharmacol Exp Ther; 2003 Jan; 304(1):272-6. PubMed ID: 12490601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques.
    Ramanathan-Girish S; Catz P; Creek MR; Wu B; Thomas D; Krogstad DJ; De D; Mirsalis JC; Green CE
    Int J Toxicol; 2004; 23(3):179-89. PubMed ID: 15204721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
    Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
    J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifaceted approach to determine the antagonist molecular mechanism and interaction of ibodutant ([1-(2-phenyl-1R-[[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-ylmethyl]-carbamoyl]-ethylcarbamoyl)-cyclopentyl]-amide) at the human tachykinin NK2 receptor.
    Meini S; Bellucci F; Catalani C; Cucchi P; Giolitti A; Santicioli P; Giuliani S
    J Pharmacol Exp Ther; 2009 May; 329(2):486-95. PubMed ID: 19218528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of a peripheral role of neurokinins in detrusor hyperreflexia: a further study of selective tachykinin antagonists in chronic spinal injured rats.
    Abdel-Gawad M; Dion SB; Elhilali MM
    J Urol; 2001 May; 165(5):1739-44. PubMed ID: 11342967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
    Halpin RA; Geer LA; Zhang KE; Marks TM; Dean DC; Jones AN; Melillo D; Doss G; Vyas KP
    Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of a novel histone deacetylase inhibitor, apicidin, in rats.
    Shin BS; Chang HS; Park EH; Yoon CH; Kim HY; Kim J; Ryu JK; Zee OP; Lee KC; Cao D; Yoo SD
    Biopharm Drug Dispos; 2006 Mar; 27(2):69-75. PubMed ID: 16299816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
    Sterious SN; Walker EA
    J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of a C5a receptor antagonist in the rat after different sites of enteral administration.
    Morgan M; Bulmer AC; Woodruff TM; Proctor LM; Williams HM; Stocks SZ; Pollitt S; Taylor SM; Shiels IA
    Eur J Pharm Sci; 2008 Apr; 33(4-5):390-8. PubMed ID: 18337070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.